Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations

European Radiology

Volumn 25, Issue 5, 2015, Pages 1257-1266

  Zhou, J Y ^a   Zheng, J ^a   Yu, Z F ^a   Xiao, W B ^a   Zhao, J ^a   Sun, K ^a   Wang, B ^a   Chen, X ^a   Jiang, L N ^a   Ding, W ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ALK; EGFR; Lung cancer; Percentage of ground glass opacity volume; Tumour shadow disappearance rate

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; IOPROMIDE; PROTEIN TYROSINE KINASE;

ADULT; AGED; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMAGING SOFTWARE; LUNG ADENOCARCINOMA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; RECEPTOR GENE; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME; ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; LUNG TUMOR; MUTATION; PROCEDURES; RADIOGRAPHY; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84928139764     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-014-3516-z     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A et al (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10–29
2. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–57
3. Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380–8
4. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–39
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–32
6. Stinchcombe TE, Socinski MA (2008) Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? Oncologist 13(9):933–44
7. Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496):1527–37
8. Shaw AT, Engelman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31(8):1105–11
9. Forde PM, Rudin CM et al (2012) Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 13(8):1195–201
10. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–703
11. Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. J Mol Diagn 15(4):415–53
12. Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–500
13. Lee HJ, Kim YT, Kang CH et al (2013) Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. Radiology 268(1):254–64
14. Wong DW, Leung EL, So KK et al (2009) The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723–33
15. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3:13–7
16. Takahashi T, Sonobe M, Kobayashi M et al (2009) Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 17:889–97
17. Fukui T, Yatabe Y, Kobayashi Y et al (2012) Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 77(2):319–25
18. American Joint Commission on Cancer (2009) 7th ed. Chicago, Ill: Springer
19. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F (2011) Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 30:57
20. Marten K, Engelke C et al (2007) Computer-aided detection and automated CT volumetry of pulmonary nodules. Eur Radiol 17(4):888–901
21. Hansell DM, Bankier AA, MacMahon H et al (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246(3):697–722
22. Quaia E, Baratella E, Pizzolato R et al (2009) Radiological-pathological correlation in intra-tumoural tissue components of solid lung tumours. Radiol Med 114(2):173–89
23. Ikehara M, Saito H, Kondo T et al (2012) Comparison of thin-section CT and pathological findings in small solid-density type pulmonary adenocarcinoma: prognostic factors from CT findings. Eur J Radiol 81(1):189–94
24. Shimizu K, Yamada K, Saito H, Noda K, Nakayama H, Kameda Y et al (2005) Surgically curable peripheral lung carcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Chest 127:871–8
25. Okada M, Nishio W, Sakamoto T et al (2003) Discrepancy of computed tomographic image between lung and mediastinal windows as a prognostic implication in small lung adenocarcinoma. Ann Thorac Surg 76:1828–32
26. Takamochi K, Nagai K, Yoshida J et al (2002) Pathologic N0 status in pulmonary adenocarcinoma is predictable by combining serum carcinoembryonic antigen level, and computed tomographic findings. J Thorac Cardiovasc Surg 122:325–30
27. Yoshida A, Tsuta K, Nakamura H et al (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35(8):1226–34
28. Rodig SJ, Mino-Kenudson M, Dacic S et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216–23
29. Glynn C, Zakowski MF, Ginsberg MS (2010) Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? J Thorac Oncol 5(3):344–8
30. Lee JK, Kim TM, Koh Y et al (2012) Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 77(2):460–3
31. Boland JM, Jang JS, Li J et al (2013) MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol 8(5):574–81